Latest Headlines

  1. Bambusa Therapeutics Announces First Subject Dosed In Phase 1 Clinical Trial Of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody For Broad I&I Conditions And U.S. FDA Clearance Of IND Application For BBT001 5/30/2025

    Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the initial dosing in healthy volunteers (HV) in its clinical trial for BBT002, a novel, half-life extended bispecific antibody designed as a "platform in a molecule" with broad applications across respiratory, dermatology, and gastroenterology.

  2. Astellas Enters Exclusive License Agreement With Evopoint Biosciences For XNW27011, A Novel Clinical-Stage Antibody-Drug Conjugate Targeting CLDN18.2 5/29/2025

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2.

  3. Charles River And CHDI Foundation Extend Multi-Decade Collaboration On Huntington's Disease Research 5/28/2025

    Charles River Laboratories International, Inc. and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future.

  4. HCVC Leads kyron.bio €5.5M Round To Use Glycan Engineering For Advanced Drug Design 5/28/2025

    One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company kyron.bio today announced a €5.5 million funding round to solve these issues using precise control of sugar molecules found on the surface of a drug - also known as glycans.

  5. Eton Pharmaceuticals Announces U.S. FDA Approval For KHINDIVI™ (Hydrocortisone) Oral Solution 5/28/2025

    Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for KHINDIVI™ (hydrocortisone) Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency.

  6. Nuclera And Cytiva Join Forces To Accelerate Drug Discovery 5/28/2025

    At Nuclera, we’re driven by a single goal: to revolutionize protein expression and optimization. That’s why we’re excited to share news of our latest collaboration with Cytiva, a global leader in life sciences.

  7. Radyus Research And Eurofins CDMO Alphora Announce Strategic Partnership To Accelerate And Optimize Drug Development 5/28/2025

    Radyus Research, a U.S.-based drug development organization, and Eurofins CDMO Alphora, a Canadian contract development and manufacturing organization announced a new strategic partnership to help accelerate early-stage drug development for biotech companies worldwide.

  8. Nuclera And Cytiva Collaborate To Accelerate Characterization Of Proteins For Drug Development 5/28/2025

    Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery System, has announced a collaboration with Cytiva, a global life sciences leader.

  9. Selvita Acquires License For Medicines Discovery Catapult's Patented Target Engagement Technology 5/27/2025

    Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.

  10. GSK's Depemokimab Accepted For Review By Health Canada For The Treatment Of Asthma With Type 2 Inflammation And For Chronic Rhinosinusitis With Nasal Polyps 5/26/2025

    GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller.